220 related articles for article (PubMed ID: 24130051)
1. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
Ronca R; Di Salle E; Giacomini A; Leali D; Alessi P; Coltrini D; Ravelli C; Matarazzo S; Ribatti D; Vermi W; Presta M
Mol Cancer Ther; 2013 Dec; 12(12):2760-71. PubMed ID: 24130051
[TBL] [Abstract][Full Text] [Related]
2. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.
Giacomini A; Matarazzo S; Pagano K; Ragona L; Rezzola S; Corsini M; Di Salle E; Presta M; Ronca R
Oncotarget; 2015 May; 6(15):13790-802. PubMed ID: 25912421
[TBL] [Abstract][Full Text] [Related]
3. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
Rusnati M; Camozzi M; Moroni E; Bottazzi B; Peri G; Indraccolo S; Amadori A; Mantovani A; Presta M
Blood; 2004 Jul; 104(1):92-9. PubMed ID: 15031207
[TBL] [Abstract][Full Text] [Related]
4. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.
Leali D; Alessi P; Coltrini D; Ronca R; Corsini M; Nardo G; Indraccolo S; Presta M
Mol Cancer Ther; 2011 Sep; 10(9):1600-10. PubMed ID: 21764903
[TBL] [Abstract][Full Text] [Related]
5. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
[TBL] [Abstract][Full Text] [Related]
7. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.
Camozzi M; Zacchigna S; Rusnati M; Coltrini D; Ramirez-Correa G; Bottazzi B; Mantovani A; Giacca M; Presta M
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1837-42. PubMed ID: 16020751
[TBL] [Abstract][Full Text] [Related]
8. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.
Leali D; Inforzato A; Ronca R; Bianchi R; Belleri M; Coltrini D; Di Salle E; Sironi M; Norata GD; Bottazzi B; Garlanda C; Day AJ; Presta M
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):696-703. PubMed ID: 22267482
[TBL] [Abstract][Full Text] [Related]
9. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Ronca R; Giacomini A; Di Salle E; Coltrini D; Pagano K; Ragona L; Matarazzo S; Rezzola S; Maiolo D; Torrella R; Moroni E; Mazzieri R; Escobar G; Mor M; Colombo G; Presta M
Cancer Cell; 2015 Aug; 28(2):225-39. PubMed ID: 26267536
[TBL] [Abstract][Full Text] [Related]
10. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2.
Presta M; Foglio E; Churruca Schuind A; Ronca R
Front Immunol; 2018; 9():2327. PubMed ID: 30349543
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Proliferation and Epithelial Mesenchymal Transition in Retinal Pigment Epithelial Cells by Heavy Chain-Hyaluronan/Pentraxin 3.
He H; Kuriyan AE; Su CW; Mahabole M; Zhang Y; Zhu YT; Flynn HW; Parel JM; Tseng SC
Sci Rep; 2017 Mar; 7():43736. PubMed ID: 28252047
[TBL] [Abstract][Full Text] [Related]
12. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
13. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
[TBL] [Abstract][Full Text] [Related]
14. Pentraxin 3 Activates JNK Signaling and Regulates the Epithelial-To-Mesenchymal Transition in Renal Fibrosis.
Hung TW; Tsai JP; Lin SH; Lee CH; Hsieh YH; Chang HR
Cell Physiol Biochem; 2016; 40(5):1029-1038. PubMed ID: 27941350
[TBL] [Abstract][Full Text] [Related]
15. Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth.
Rodrigues PF; Matarazzo S; Maccarinelli F; Foglio E; Giacomini A; Silva Nunes JP; Presta M; Dias AAM; Ronca R
Front Oncol; 2018; 8():472. PubMed ID: 30443492
[TBL] [Abstract][Full Text] [Related]
16. The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach.
Rezzola S; Ronca R; Loda A; Nawaz MI; Tobia C; Paganini G; Maccarinelli F; Giacomini A; Semeraro F; Mor M; Presta M
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31487962
[TBL] [Abstract][Full Text] [Related]
17. Oleate-induced PTX3 promotes head and neck squamous cell carcinoma metastasis through the up-regulation of vimentin.
Chan SH; Tsai JP; Shen CJ; Liao YH; Chen BK
Oncotarget; 2017 Jun; 8(25):41364-41378. PubMed ID: 28489600
[TBL] [Abstract][Full Text] [Related]
18. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of hepatoma-derived growth factor facilitates tumor progression in malignant melanoma [corrected].
Tsai HE; Wu JC; Kung ML; Liu LF; Kuo LH; Kuo HM; Chen SC; Chan EC; Wu CS; Tai MH; Liu GS
PLoS One; 2013; 8(3):e59345. PubMed ID: 23536873
[TBL] [Abstract][Full Text] [Related]
20. Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells.
O'Neill CL; Guduric-Fuchs J; Chambers SE; O'Doherty M; Bottazzi B; Stitt AW; Medina RJ
Cardiovasc Res; 2016 Dec; 112(3):677-688. PubMed ID: 27659714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
